Alzheimer's disease and fragile X syndrome: The Wnt/β-catenin pathway as a common biological mechanism;Enfermedad de Alzheimer y síndrome X frágil: La vía Wnt-β-catenina como mecanismo biológico común

Revista de Neurologia

Volumn 55, Issue 9, 2012, Pages 543-548

  Rosales Reynoso, Mónica Alejandra ^a   Ochoa Hernández, Alejandra Berenice ^a   Juárez Vázquez, Clara Ibet ^a   Barros Núñez, Patricio ^a  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA DE OCCIDENTE   (Mexico)

Author keywords

Alzheimer's disease; Apoptosis; Cancer; Fragile X syndrome; Neurodegeneration; Wnt catenin

Indexed keywords

BETA CATENIN; WNT PROTEIN;

ALZHEIMER DISEASE; APOPTOSIS; CANCER RISK; CELL CYCLE; DISEASE COURSE; FRAGILE X SYNDROME; METABOLISM; REVIEW; WNT SIGNALING PATHWAY;

EID: 84868517536     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5509.2012450     Document Type: Review

References (50)

1. Robinson R. Protein-RNA interaction links fragile X syndrome and Alzheimer disease. PLoS Biol 2007; 5: e84.
2. Malter JS, Ray BC, Westmark PR, Westmark CJ. Fragile X syndrome and Alzheimer's disease: another story about APP and beta-amyloid. Curr Alzheimer Res 2010; 7: 200-6.
3. Westmark CJ, Malter JS. FMRP mediates mGluR5-dependent translation of amyloid precursor protein. PLoS Biol 2007; 5: e52.
4. Darnell JC, Jensen KB, Jin P, Brown V, Warren ST, Darnell RB. Fragile X mental retardation protein targets G quartet mRNAs important for neuronal function. Cell 2001; 107: 489-99.
5. Warren ST, Sherman SL. The fragile X syndrome. In Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic basis of inherited disease. 7 ed. New York: McGraw-Hill; 2001. p. 795-810.
6. Online Mendelian Inheritance in Man, OMIM (TM). McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University and National Center for Biotechnology Information, National Library of Medicine, 2012. URL: http:// www.ncbi.nlm.nih.gov/omim/.
7. Jin P, Warren ST. Understanding the molecular basis of fragile X syndrome. Hum Mol Genet 2000; 9: 901-8.
8. Glóver-López G, Guillén-Navarro E. Síndrome X frágil. Rev Neurol 2006; 42 (Supl 1): S51-4.
9. Luo Y, Shan G, Guo W, Smrt RD, Johnson EB, Li X, et al. Fragile X mental retardation protein regulates proliferation and differentiation of adult neural stem/progenitor cells. PLoS Genet 2010; 6: 1-15.
10. Hayes EW, Matalon R. Fragile X syndrome. Pediatrics 2009; 124: 790-2.
11. Rosales-Reynoso MA, Ochoa-Hernández AB, Aguilar-Lemarroy A, Jave-Suárez LF, Troyo-Sanromán R, Barros-Núñez P. Gene expression profiling identifies WNT7A as a possible candidate gene for decreased cancer risk in fragile X syndrome patients. Arch Med Res 2010; 41: 110-8.
12. Schultz-Pedersen S, Hasle H, Olsen JH, Friedrich U. Evidence of decreased risk of cancer in individuals with fragile X. Am J Med Genet 2001; 103: 226-30.
13. Sund R, Pukkala E, Patja K. Cancer incidence among persons with fragile X syndrome in Finland: a population-based study. J Intellect Disabil Res 2009; 53: 85-90.
14. Castro-Volio I, Cuenca-Berger P. Trastornos del neurodesarrollo (síndrome X frágil) y neurodegenerativos (síndrome de temblor/ ataxia) asociados al crecimiento de un gen. Rev Neurol 2005; 40: 431-7.
15. Greco CM, Berman RF, Martin RM, Tassone F, Schwartz PH, Chang A, et al. Neuropathology of fragile X-associated tremor/ataxia syndrome (FXTAS). Brain 2006; 129: 243-55.
16. Hagerman PJ, Hagerman RJ. Fragile X-associated tremor/ ataxia syndrome (FXTAS). Ment Retard Dev Disabil Res Rev 2004; 10: 25-30.
17. Hagerman PJ, Greco CM, Hagerman RJ. A cerebellar tremor/ataxia syndrome among fragile X premutation carriers. Cytogenet Genome Res 2003; 100: 206-12.
18. Hessl D, Rivera SM, Reiss AL. The neuroanatomy and neuroendocrinology of fragile X syndrome. Ment Retard Dev Disabil Res Rev 2004; 10: 17-24.
19. Toft M, Aasly J, Bisceglio G, Adler CH, Uitti RJ, Krygowska-Wajs A, et al. Parkinsonism, FXTAS, and FMR1 premutations. Mov Disord 2005; 20: 230-2.
20. Greco CM, Hagerman RJ, Tassone F, Chudley AE, Del Bigio MR, Jacquemont S, et al. Neuronal intranuclear inclusions in a new cerebellar tremor/ataxia syndrome among fragile X carriers. Brain 2002; 125: 1760-71.
21. Hagerman PJ, Hagerman RJ. The fragile-X premutation: a maturing perspective. Am J Hum Genet 2004; 74: 805-16.
22. Tassone F, Iwahashi C, Hagerman PJ. FMR1 RNA within the intranuclear inclusions of fragile X-associated tremor/ataxia syndrome (FXTAS). RNA Biol 2004; 1: 103-5.
23. Wenzel HJ, Hunsaker MR, Greco CM, Willemsen R, Berman RF. Ubiquitin-positive intranuclear inclusions in neuronal and glial cells in a mouse model of the fragile X premutation. Brain Res 2010; 1318: 155-66.
24. Setó-Salvia N, Clarimón J. Genética en la enfermedad de Alzheimer. Rev Neurol 2010; 50: 360-4.
25. Behrens M, Lendon C, Roe CM. A common biological mechanism in cancer and Alzheimer disease. Curr Alzheimer Res 2009; 6: 196-204.
26. Caricasole A, Bakker A, Copani A, Nicoletti F, Gaviraghi G, Terstappen GC. Two sides of the same coin: Wnt signaling in neurodegeneration and neuro-oncology. Biosci Rep 2005; 25: 309-27.
27. Adams PD, Enders GH. Wnt signaling and senescence: a tug of war in early neoplasia? Cancer Biol Ther 2008; 11: 1706-11.
28. Ghanevati M, Miller CA. Phospho-beta-catenin accumulation in Alzheimer's disease and in aggresomes attributable to proteasome dysfunction. J Mol Neurosci 2005; 25: 79-94.
29. Kukull WA, Higdon R, Bowen JD, McCormick WC, Teri L, Schellenberg GD, et al. Dementia and Alzheimer disease incidence: a prospective cohort study. Arch Neurol 2002; 59: 1737-46.
30. Inestrosa NC, Toledo EM. The role of Wnt signaling in neuronal dysfunction in Alzheimer's disease. Mol Neurodegener 2008; 3: 9.
31. De Ferrari GV, Chacon MA, Barria MI, Garrido JL, Godoy JA, Olivares G, et al. Activation of Wnt signaling rescues neurodegeneration and behavioral impairments induced by beta-amyloid fibrils. Mol Psychiatry 2003; 8: 195-208.
32. Álvarez AR, Godoy JA, Mullendorff K, Olivares GH, Bronfman M, Inestrosa NC. Wnt-3a overcomes β-amyloid toxicity in rat hippocampal neurons. Exp Cell Res 2004; 297: 186-96.
33. Busciglio J, Lorenzo A, Yeh J, Yankner BA. Βeta-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron 1995; 14: 879-88.
34. Takashima A, Honda T, Yasutake K, Michel G, Murayama O, Murayama M, et al. Activation of tau protein kinase I/ glycogen synthase kinase-3beta by amyloid beta peptide (25-35) enhances phosphorylation of tau in hippocampal neurons. Neurosci Res 1998; 31: 317-23.
35. Nunes PV, Forlenza OV, Gattaz WF. Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder. Br J Psychiatry 2007; 190: 359-60.
36. Caruso A, Motolese M, Iacovelli L, Caraci F, Copani A, Nicoletti F, et al. Inhibition of the canonical Wnt signaling pathway by apolipoprotein E4 in PC12 cells. J Neurochem 2006; 98: 364-71.
37. De Ferrari GV, Papassotiropoulos A, Biechele T, Wavrant De-Vrieze F, Avila ME, Major MB, et al. Common genetic variation within the low-density lipoprotein receptor-related protein 6 and late-onset Alzheimer's disease. Proc Natl Acad Sci U S A 2007; 104: 9434-9.
38. De Ferrari GV, Inestrosa NC. Wnt signaling functions in Alzheimer's disease. Brain Res Brain Res Rev 2000; 33: 1-12.
39. Mudher A, Lovestone S. Alzheimer's disease-do tauists and baptists finally shake hands? Trends Neurosci 2002; 25: 22-6.
40. Li HL, Wang HH, Liu SJ, Deng YQ, Zhang YT, Tian Q, et al. Phosphorylation of tau antagonizes apoptosis by stabilizing beta-catenin, a mechanism involved in Alzheimer's neurodegeneration. Proc Natl Acad Sci U S A 2007; 104: 3591-6.
41. Kalani MY, Cheshier SH, Cord BJ, Bababeygy SR, Vogel H, Weissman IL, et al. Wnt-mediated self-renewal of neural stem/ progenitor cells. Proc Natl Acad Sci U S A 2008; 105: 16970-5.
42. Song H, Kempermann G, Overstreet Wadiche L, Zhao C, Schinder AF, Bischofberger J. New neurons in the adult mammalian brain: synaptogenesis and functional integration. J Neurosci 2005; 25: 10366-8.
43. Zhao C, Deng W, Gage FH. Mechanisms and functional implications of adult neurogenesis. Cell 2008; 132: 645-60.
44. Gulacsi A, Anderson S. β-catenin-mediated Wnt signaling regulates neurogenesis in the ventral telencephalon. Nat Neurosci 2008; 11: 1383-91.
45. Tyner SD, Venkatachalam S, Choi J, Jones S, Ghebranious N, Ingelman H, et al. p53 mutant mice that display early ageing associated phenotypes. Nature 2002; 415: 45-53.
46. Khalil AM, Faghihi MA, Modarresi F, Brothers SP, Wahlestedt C. A novel RNA transcript with antiapoptotic function is silenced in fragile X syndrome. PLoS One 2008; 3: e1486.
47. Reiss AL, Lee J, Freund L. Neuroanatomy of fragile X syndrome: the temporal lobe. Neurology 1994; 44: 1317-24.
48. Freund LS, Reiss AL. Cognitive profiles associated with the fra (X) syndrome in males and females. Am J Med Genet 1991; 38: 542-7.
49. Mazzocco MM, Freund L, Baumgardner TL, Forman L, Reiss AL. The neurobehavioral and neuroanatomical effects of the FMR1 full mutation: monozygotic twins discordant for fragile X syndrome. Neuropsychology 1995; 9: 470-80.
50. Kates WR, Abrams MT, Kaufmann WE, Breiter SN, Reiss AL. Reliability and validity of MRI measurement of the amygdale and hippocampus in children with fragile X syndrome. Psychiatry Res 1997; 75: 31-48.